Literature DB >> 6996624

Response of renal allograft recipients to pneumococcal vaccine.

H Silberman, G D Overturf, R J Field, J Butler, T V Berne, R Witt.   

Abstract

Antibody responses to pneumococcal polysaccharide vaccine were compared in a control group of 17 normal adults and in a group of 27 adult patients with stable renal function (serum creatinine 0.8--2.1 mg/dl) seven months to nine years following renal transplantation. Using the indirect hemagglutination technique, antibody titers to 13 of the 14 capsular antigens contained in the vaccine were determined for each patient just prior to and again three weeks following immunization. There was no significant difference between the two groups in the proportion of patients responding with a fourfold rise in titer to 12 of the 13 antigens tested. The response rate to antigen type 3 was reduced in the transplant group (p less than 0.05). Mean fold increase in indirect hemagglutination titers was likewise determined for each antigen, and a reduced response in the transplant group was noted only to antigen type 23 (p = 0.037). Immunosuppressed renal allograft recipients appear capable of mounting a nearly normal antibody response to pneumococcal vaccine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6996624      PMCID: PMC1344853          DOI: 10.1097/00000658-198008000-00012

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  10 in total

1.  Prevention of pneumococcal pneumonia by vaccination.

Authors:  R Austrian; R M Douglas; G Schiffman; A M Coetzee; H J Koornhof; S Hayden-Smith; R D Reid
Journal:  Trans Assoc Am Physicians       Date:  1976

2.  Maxwell Finland Lecture. Random gleanings from a life with the pneumococcus.

Authors:  R Austrian
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

3.  Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease.

Authors:  G R Siber; S A Weitzman; A C Aisenberg; H J Weinstein; G Schiffman
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

4.  Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy.

Authors:  A J Ammann; J Addiego; D W Wara; B Lubin; W B Smith; W C Mentzer
Journal:  N Engl J Med       Date:  1977-10-27       Impact factor: 91.245

5.  Pneumococcal infection and pneumococcal vaccine.

Authors:  R Austrian
Journal:  N Engl J Med       Date:  1977-10-27       Impact factor: 91.245

6.  Severe pneumonia in renal transplant patients. One year's experience.

Authors:  W A Briggs; J P Merrill; T F O'Brien; R E Wilson; A G Birtch; J E Murray
Journal:  Ann Intern Med       Date:  1971-12       Impact factor: 25.391

7.  Risk of pneumococcal infections in renal transplant patients.

Authors:  C C Linnemann; M R First
Journal:  JAMA       Date:  1979-06-15       Impact factor: 56.272

8.  Pulmonary infections in renal transplant recipients.

Authors:  R Munda; J W Alexander; M R First; P S Gartside; J P Fidler
Journal:  Ann Surg       Date:  1978-02       Impact factor: 12.969

9.  Determination of antibody to pneumococcal polysaccharides with chromic chloride-treated human red blood cells and indirect hemagglutination.

Authors:  A J Ammann; R J Pelger
Journal:  Appl Microbiol       Date:  1972-11

10.  Severe infection due to Streptococcus pneumoniae in asplenic renal transplant patients.

Authors:  A M Bourgault; R E Van Scoy; C J Wilkowske; S Sterioff
Journal:  Mayo Clin Proc       Date:  1979-02       Impact factor: 7.616

  10 in total
  2 in total

1.  Assessment of humoral and cell-mediated immune response to measles-mumps-rubella vaccine viruses among patients with asthma.

Authors:  Kwang Ha Yoo; Kanishtha Agarwal; Michael Butterfield; Robert M Jacobson; Gregory A Poland; Young J Juhn
Journal:  Allergy Asthma Proc       Date:  2010 Nov-Dec       Impact factor: 2.587

2.  Atopic eczema is associated with delayed maturation of the antibody response to pneumococcal vaccine.

Authors:  P D Arkwright; L Patel; A Moran; M R Haeney; C I Ewing; T J David
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.